Compare RLAY & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLAY | PBLS |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 2020 | 2026 |
| Metric | RLAY | PBLS |
|---|---|---|
| Price | $18.66 | $38.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 351.6K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $3.89 | $25.56 |
| 52 Week High | $21.27 | $41.49 |
| Indicator | RLAY | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 56.63 |
| Support Level | $18.00 | $37.88 |
| Resistance Level | $20.82 | $41.49 |
| Average True Range (ATR) | 0.80 | 1.93 |
| MACD | -0.13 | -0.28 |
| Stochastic Oscillator | 28.24 | 31.28 |
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.